Kala Pharmaceuticals (NASDAQ:KALA) Lowered to “Hold” at Zacks Investment Research
According to Zacks, “Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts and the female reproductive systems. Kala Pharmaceuticals, Inc. is based in Waltham, United States. “
A number of other equities analysts also recently commented on the stock. BidaskClub downgraded shares of Kala Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, April 16th. HC Wainwright cut their target price on shares of Kala Pharmaceuticals from $15.00 to $12.00 and set a buy rating for the company in a research note on Wednesday, August 7th. Oppenheimer set a $9.00 target price on shares of Kala Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, August 7th. Wedbush reiterated an outperform rating and issued a $51.00 target price on shares of Kala Pharmaceuticals in a research note on Wednesday, August 7th. Finally, ValuEngine upgraded shares of Kala Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Kala Pharmaceuticals has an average rating of Buy and an average target price of $18.54.
Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.70) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.04. The business had revenue of $2.06 million for the quarter, compared to analyst estimates of $2.62 million. As a group, sell-side analysts expect that Kala Pharmaceuticals will post -2.81 earnings per share for the current year.
In other news, Director Howard B. Rosen bought 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 30th. The stock was acquired at an average cost of $5.42 per share, for a total transaction of $27,100.00. Following the purchase, the director now owns 8,240 shares of the company’s stock, valued at approximately $44,660.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 30.77% of the company’s stock.
Large investors have recently modified their holdings of the stock. BlackRock Inc. raised its holdings in Kala Pharmaceuticals by 20.3% in the 2nd quarter. BlackRock Inc. now owns 1,684,802 shares of the company’s stock valued at $10,749,000 after acquiring an additional 283,747 shares during the period. Vanguard Group Inc. increased its holdings in shares of Kala Pharmaceuticals by 25.1% during the second quarter. Vanguard Group Inc. now owns 1,237,683 shares of the company’s stock worth $7,896,000 after purchasing an additional 248,287 shares during the period. Deutsche Bank AG increased its holdings in shares of Kala Pharmaceuticals by 349.6% during the fourth quarter. Deutsche Bank AG now owns 268,054 shares of the company’s stock worth $1,310,000 after purchasing an additional 208,436 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Kala Pharmaceuticals by 62.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 255,760 shares of the company’s stock worth $1,251,000 after purchasing an additional 98,591 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Kala Pharmaceuticals by 79.4% during the fourth quarter. Geode Capital Management LLC now owns 199,935 shares of the company’s stock worth $977,000 after purchasing an additional 88,484 shares during the period. Institutional investors and hedge funds own 69.67% of the company’s stock.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Featured Article: What is the Stochastic Momentum Index (SMI)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.